Clinical Trial Update: A Study of GC203 TIL in PDCA (RJ) [EARLY_Phase 1]

View source ↗

Summary

Phase 1 study evaluating GC203 TIL therapy for pancreatic cancer, including pancreatic ductal adenocarcinoma. The trial is currently recruiting in Shanghai.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• GC203 TIL

Snippet

Sponsor: Shanghai Juncell Therapeutics | Conditions: Pancreatic Cancer, Pancratic Ductal Adenocarcinoma | EARLY_Phase 1 | Status: RECRUITING